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Deletion and Point Mutations of PTHLH
Cause Brachydactyly Type E
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Eveline Blom,4 Yves Gillerot,5 Johannes F.W. Weigel,6 Gabriele Kru¨ger,7 Olaf Hiort,8 Petra Seemann,9
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Autosomal-dominant brachydactyly type E (BDE) is a congenital limb malformation characterized by small hands and feet predomi-
nantly as a result of shortened metacarpals and metatarsals. In a large pedigree with BDE, short stature, and learning disabilities, we de-
tected a microdeletion of ~900 kb encompassing PTHLH, the gene coding for parathyroid hormone related protein (PTHRP). PTHRP is
known to regulate the balance between chondrocyte proliferation and the onset of hypertrophic differentiation during endochondral
bone development. Inactivation of Pthrp in mice results in short-limbed dwarﬁsm because of premature differentiation of chondrocyte.
On the basis of our initial ﬁnding, we tested further individuals with BDE and short stature for mutations in PTHLH. We identiﬁed two
missense (L44P and L60P), a nonstop (X178WextX*54), and a nonsense (K120X) mutation. The missense mutation L60P was tested in
chicken micromass culture with the replication-competent avian sarcoma leukosis virus retroviral expression system and was shown to
result in a loss of function. Thus, loss-of-function mutations in PTHLH cause BDE with short stature.Brachydactylies are a family of limbmalformations charac-
terized by short hands and/or feet because of aplastic or
hypoplastic skeletal elements.1 Brachydactyly type E
(BDE [MIM 113300]) is characterized by a general short-
ening of metacarpals and metatarsals and/or phalanges.
The phenotype is variable even within families, ranging
from moderate shortening of individual metacarpals to
a shortening of all bones in the hands and/or feet. BDE
occurs as an isolated trait or as part of more complex syn-
dromic conditions such as hypertension-brachydactyly
syndrome [MIM 112410], Turner syndrome, or Albright
hereditary osteodystrophy (AHO [MIM 103580]). Isolated
BDE has been associated in sporadic cases with microdele-
tions of 2q37, as well as with mutations in HOXD13 [MIM
142989].2,3 However, the genetic cause of the great
majority of BDE cases remains unexplained.
Here we describe a disease gene for BDE in ﬁve unrelated
families. The pedigrees and the phenotype of affected indi-
viduals are shown in Figure 1 and Figure 2, respectively.
In family 1, the phenotype was variable, but complete
penetrance was observed. All affected presented with clin-
ical features typical for BDE, i.e., shortening of the meta-
carpals, metatarsals, and phalanges in hands and feet
with the fourth and ﬁfth metacarpals being most fre-
quently and most severely affected. In addition, hypo-
plastic middle and distal phalanges were observed in severe
cases (Figures 2A and 2E). In total, six of eight affected indi-
viduals presented with short stature (between 2.0 and
2.8 standard deviation [SD] < P3). The growth chart of
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434 The American Journal of Human Genetics 86, 434–439, March 1were noted in all affected of family 1, but not in the other
families. G stimulatory (Gs)-alpha activity in erythrocytes
was measured in family 1, but no abnormality was
detected. To perform a genetic analysis, we obtained blood
samples from all available family members and extracted
DNA by standard methods. All participants gave their
informed consent for molecular testing. The study was
approved by the local ethics committee. All affected of
the families described here were screened for mutations
in GNAS (formerly GNAS1 [MIM 139320]) and HOXD13,
but nomutation was detected. All sequencing experiments
were carried out by standard techniques as reported else-
where.4,5
Because submicroscopic aberrations are a known cause
for congenital limb malformations and brachydactylies,6–8
we performed array-based comparative genomic hybridiza-
tion (array CGH) via a whole-genome oligonucleotide
array (244K, Agilent Technologies). With this technology,
a microdeletion of about 907.68 kb on chromosome 12p
was identiﬁed that encompassed six known genes: STK38L
(disrupted), ARNTL2, C12orf70, PPFIBP1, MRPS35 [MIM
611995], KLHDC5, and PTHLH (parathyroid hormone-like
hormone [MIM 168470]; also known by its product,
parathyroid hormone-related protein, PTHRP) (Figure 3;
data deposited in the DECIPHER database with ID
BER251557). The deletion was conﬁrmed by quantitative
real-time PCR (qPCR) and was shown to segregate with
the phenotype in the affected family members (position
of amplicons indicated by arrows in Figure 3). Of the
deleted genes, only PTHLH is known to play a criticalBerlin, Germany; 2Centre for Human Genetics, University Hospital Leuven,
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Figure 1. Pedigrees of Families 1–5
Affected individuals are indicated by black
symbols. Symbols with crossed lines indi-
cate individuals of whom material was
available for testing, and stars indicate
individuals of whom clinical or X-ray
images are shown in Figure 2.role in skeletal development, suggesting that PTHLH was
the main candidate gene for BDE. To test this hypothesis,
we investigated further individuals with typical BDE by
qPCR and by sequencing all known PTHLH isoforms,
including introns and UTR regions, to detect deletions asFigure 2. Clinical Phenotypes
(A–D) Family 1, IV-3 (large deletion). Note severe BDE phenotype with small hands (A and C
metacarpals and second to ﬁfth metatarsals (arrows on X-rays). Note additional shortened m
(E and F) Family 2, II-1 (missense mutation L60P). Note small hands with shortened thi
phalanges of index and ﬁfth ﬁnger are short (E, stars).
(G) Family 3, II-1 (missense mutation L44P). Besides shortened metacarpals III–V, note cone-
and premature closure of the metacarpal epiphyses at the age of 9 years. Epiphyses of ulnar
(H) Family 4, III-1 (nonstop mutation). Note shortened third and ﬁfth metacarpals and abn
metaphyses (arrow).
(I) Growth chart of female individuals from family 1 (IV-15) and family 2 (II-1). Note that g
prematurely, resulting in small stature.
The American Journal of Human Gwell as point mutations (primer
sequences are available on request).
With this approach, we identiﬁed
two missense mutations, a nonstop
mutation as well as a nonsense muta-
tion.
In a 41-year-old female with short
metacarpals III–V, short middle pha-
langes of digits II and V, and short
stature (2.97 SD < P3) (family 2;
Figures 2E and 2F; growth chart in
Figure 2I), we detected a missensemutation (c.179T>C) in exon 3 that changes the con-
served amino acid leucine to proline (p.L60P). A further
heterozygous missense mutation (c.131T>C) was detected
in family 3, which results in a similar amino acid change
(p.L44P). The affected individual presented with normal) and feet (B and D) due to shortening of all
iddle phalanx of digits II and V (A, stars).
rd to ﬁfth metacarpals. Middle and distal
shaped epiphyses at the phalanges (arrows)
and radius appear irregular and ﬂattened.
ormal epiphyses prematurely fused to their
rowth velocity of affected individuals stops
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Figure 3. Mutations Associated with BDE
An ~907 kb genomic microdeletion on chromosome 12p was detected in family 1 affecting six genes (gray bar, top; ISCN2009: array
12p11.23p11.22(27,341,677-28,249,358)x1). Point mutations within the PTHLH gene observed in families 2–5 are indicated (bottom).
Genes are shown as dark gray boxes, with transcriptional orientation indicated by arrow heads. Small arrows point to genomic position
of qPCR amplicons. Exon structure of PTHLH gene is according to NM_198966. Location of the start codon (ATG) in exon 2 is indicated.
Genomic positions are according to hg18.
Top: 1 mm represents 5 kb. Bottom: exons, 1 mm represents 10 bp; introns, 1 mm represents 100 bp.stature (137 cm at 9 years and 2 months; þ0.6 SD) and
BDE. X-ray at the age of 9 years showed cone-shaped
epiphyses of several phalanges and premature fusion of
epiphyses (Figure 2G). Problems with tooth eruption of
primary as well as secondary teeth were reported. Bioinfor-
matic analyses of disease potential with PolyPhen9 and
MutationTaster predicted both variations to be damaging.
Because the conserved amino acid leucine at both posi-
tions is located within an alpha helix motif, the changes
are likely to break the a-helical structure and thereby
disturb the tertiary protein structure. To test the effect of
the p.L60P mutation, we performed functional testing in
chicken micromass culture.10 Murine wild-type (WT) and
mutant Pthlh constructs were overexpressed in chicken
limb micromass culture via a retroviral system (RCASBP-A)
as described previously.11 Alkaline phosphatase (ALP)
activity was measured on day 7 and day 10 as an indicator
of late-stage chondrocyte differentiation (Figure 4). Expres-
sion of mutant Pthrp resulted in a weaker suppression of436 The American Journal of Human Genetics 86, 434–439, March 1ALP activity compared to WT (Figure 4), indicating a loss
of function in the mutant.
Another heterozygous mutation (c.532A>G) was identi-
ﬁed in family 4 that converts the stop codon in exon 4 into
tryptophan (p.X178WextX*54), resulting in an extension
of the coding region (Figure 3). This 14-year-old female
presented with shortened metacarpals III and V, abnormal
metacarpal epiphyses prematurely fused to hermetaphyses
(Figure 2H), and short stature (2.4 SD < P3). In addition,
the nails of the ﬁrst ﬁngers were hypoplastic. Her mother
also had short ﬁfth metacarpals, and the maternal grandfa-
ther was reported to have the same phenotype as the index
patient (short stature [3.6 SD < P3] and brachydactyly),
but material for testing was not available.
Transcripts lacking in-frame termination codons can
be subject to a surveillance mechanism called nonstop
decay.12 This mechanism was primarily described in
Saccharomyces cerevisiae, and transcripts are degraded 30 to
50 by the exosome independently of deadenylation.13,14Figure 4. Functional Testing of Missense
Mutation L60P in Chicken Micromass
System
WT Pthlh (B and F) and L60P mutant
(C and H) were retrovirally overexpressed
in micromass cultures from chicken limb
buds and were grown for 7 days (A–C)
and 10 days (D–F) in culture medium.
In comparison to theWT, the L60Pmutant
does not show a strong suppression of ALP
activity (D andH). However, ALP activity is
reduced compared to the uninfected
control (D and H).
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Recently, nonstop decay has also been observed as amolec-
ular mechanism in human disease.15 Thus, we propose
that the heterozygous mutation in exon 4 results in
nonstop-mediated decay of PTHLH mRNA and, conse-
quently, in a reduced amount of PTHRP protein.
In family 5 (individual II-1), we detected a heterozygous
nonsense mutation in exon 3 that changes the amino acid
lysine into a stop codon (p.K120X). This results in a trunca-
tion of the protein within the nuclear localization signal
(NLS). Because the mutation is located more than 50 bp
away from the 30 boundary of the second-to-last exon, it
may be subjected to nonsense-mediated decay. The four
single nucleotide changes were not detected in any of
200 control individuals, thus excluding a rare SNP or
copy number variant. Family 5 presented with BDE (short-
enedmetacarpals III–V), short stature, and, in addition, oli-
godontia. Patient II-1 had 9 and her sister (II-2) had 26
permanent teeth missing. Individual I-1 was reported to
have normal hands and feet and normal stature, but clin-
ical information on I-2 was not available. The observation
that two out of ﬁve families had tooth problems suggests
a role for PTHRP in tooth development and/or eruption.
In mice, PTHRP was indeed shown to be important for
normal tooth development. Philbrick et al.16 investigated
PTHrP-knockout mice with a procollagen II-driven trans-
gene that generates PTHrP expression only in cartilage.
Besides small stature, these rescued PTHrP-knockout mice
presented with a failure of tooth eruption. Although teeth
appear to develop normally, they become impacted within
the surrounding alveolar bone.16
Overall, we identiﬁed 13 affected individuals, of whom
10 were adults. Of the 13 affected, 10 had short stature
and 3 were within normal range. The average height of
adults with mutations in PTHLH was 150 cm in females
and 162 cm in males. The growth velocity of affected indi-
viduals appeared to slow down and stop prematurely,
resulting in small stature (see also growth curves in Fig-
ure 2I). Most likely, this was a result of premature closure
of growth plates. This can be observed in abnormal cone-
shaped epiphyses of the phalanges andmetacarpals, which
fuse prematurely with their metaphyses (Figures 2G and
2H). Delayed tooth eruption and/or oligodontia is an addi-
tional but not obligatory feature of this condition. Taken
together, mutations in PTHLH result in a speciﬁc type of
skeletal disease that we suggest to name ‘‘BDE with short
stature, PTHLH type.’’
Because only individuals of family 1 presented with
learning difﬁculties in addition to BDE and short stature,
the deletion of the ﬁve genes distal to PTHLH most likely
accounts for this additional phenotype. The deletion in
family 1 overlaps with a larger deletion described by Ba¨hr-
ing et al.17 in a Japanese BDE case. The latter contains the
locus previously assigned for autosomal-dominant brachy-
dactyly and hypertension (MIM 112410).18 The authors
claimed that a loss of function due to gene deletions may
cause the brachydactyly. However, the critical region
proposed for the brachydactyly-relevant gene lies approxi-The Amerimately 2 Mb distal to the deletion detected in family 1 and
does not include PTHLH.19
Parathyroid hormone-related protein (PTHRP) was
initially identiﬁed by investigators studying the causes of
hypercalcemia of malignancy. Subsequently, PTHRP was
discovered to be secreted by many types of cells including
chondrocytes, perichondrial cells, and osteoblasts. The
initial translation product of PTHRP undergoes several
endoproteolytic cleavage steps that give rise to three
distinct peptides: the NH2-terminal peptide (residues
1–37), which has PTH-like and growth regulatory activi-
ties; the midregion domain (residues 38–93), containing
a nuclear localization signal regulating calcium transport
and cell proliferation; and the COOH-terminal domain
(residues 102–141), also called osteostatin, which is known
to modulate osteoclast activity. PTHRP activates the same
receptor as PTH, i.e., the PTHRP/PTH receptor (PTHR),
leading to a stimulation of both Gs and Gq family of het-
erotrimeric G proteins. This activation results in a variety
of actions ranging from relaxation of smooth muscle cells
to regulation of proliferation and differentiation (for
review, see 20).
In developing bones, PTHLH is expressed in the distal
ends of the cartilage anlagen and in the perichondrium.
It diffuses away from its site of production and binds
to its receptor (PTHR) located on prehypertrophic chon-
drocytes. PTHRP binding to its receptor results in Gs acti-
vation, which in turn keeps chondrocytes proliferat-
ing through suppression of the cyclin-cdk inhibitor p57,
thereby increasing the pool of proliferating nondifferenti-
ated chondrocytes.20 The production of Pthrp is under
control of Ihh, as shown by various genetic experiments.21
Together, Ihh and Pthrp form a feedback loop that regu-
lates the onset of hypertrophic differentiation and thus
endochondral bone development.22 The effects of Pthrp
on chondrocyte differentiation are also mediated via the
regulation of the phosphorylation of Sox9, a transcription
factor important for chondrocyte differentiation, and by
suppressing Runx2, a transcription factor essential for oste-
oblast differentiation.23,24
The important function of PTHRP and its pathway in
endochondral bone formation are demonstrated by var-
ious gene inactivation experiments in the mouse and by
human mutations. Inactivation of Pthlh in the mouse
results in a lethal short-limbed chondrodysplasia. Growth
plate chondrocytes in these mice undergo the normal
sequence of proliferation and hypertrophy, except that
they show an accelerated maturation and thus become
hypertrophic much sooner thanWTcells.25–27 Conversely,
overexpression of Pthlh in proliferating chondrocytes
through a transgenic strategy results in profound delay of
maturation.28 In addition, inactivation of Pthlh leads to
low bone density in mice.29 However, we found no evi-
dence for osteoporosis in the families presented here.
Mice with inactivated Pthrp/Pth receptor show a very
similar phenotype as Pthlh/ mice, indicating that the
Pthrp/Pth receptor mediates most of the action of Pthrpcan Journal of Human Genetics 86, 434–439, March 12, 2010 437
on growth plate chondrocytes.30 Loss-of-function muta-
tions in the PTHRP/PTH receptor in humans result in
a recessive lethal chondrodysplasia, Blomstrand dysplasia
(MIM 215045), whereas activating mutations in the
receptor are the cause for Jansen metaphyseal dysplasia
(MIM 156400).
The primary mediator of PTHRP/PTH receptor signaling
in chondrocytes is GNAS. Haploinsufﬁciency of Gnas, the
downstream effector of Pthrp, in mice results in premature
differentiation of growth plate chondrocytes, thus resem-
bling the phenotype described for Pthrp/Pth receptor as
well as for Pthlh-deﬁcient mice.31 Mutations in GNAS in
humans cause Albright hereditary osteodystrophy (AHO),
a genetically heterogenous phenotype that includes pseu-
dohypoparathyroidism type 1a (PHP1a [MIM 13580]),
type 1c (PHP1c [MIM 612462]), and pseudopseudohypo-
parathyroidism (PPHP [MIM 612463]), the normocalcemic
variant of PHP. Mutations of the GNAS gene on chromo-
some 20q13.2 have been shown to be associated with
PHP1a and PPHP.5 GNAS encodes the Gs-alpha subunit of
the Gs protein complex. The Gs proteins transduce extra-
cellular signals from transmembrane receptors to intracel-
lular downstream effector proteins via second messengers
like cyclic AMP and activation of protein kinase A (PKA).
Interestingly, GNAS appears to be imprinted: loss-of-func-
tion mutations on the maternal allele cause PHP1A,
whereas mutations on the paternal allele result in PPHP.
AHO is associated with a variety of clinical symptoms
such as short stature, obesity, and mental retardation.
The skeletal phenotype, however, is rather uniform and
strikingly similar to the BDE phenotype described here.
Other than in association with mutations in GNAS, BDE
is observed in a large number of other conditions, some
of which are caused by mutations in molecules that are
known to interact with the PTHRP pathway. Mutations
in IHH, for example, cause acrocapitofemoral dysplasia
(MIM 607778), a condition with brachydactyly and cone-
shaped epiphyses.32 Short metacarpals are also a feature of
basal cell nevus syndrome (MIM 109400), which is caused
by mutations in PTCH1 (MIM 601309), the receptor for
Hedgehog proteins,33 and cleidocranial dysplasia (CCD
[MIM 119600]), a condition caused by mutations in
RUNX2 (MIM 600211), a direct regulator of IHH and
a downstream target of PTHRP.34 These results suggest
that the IHH-PTHRP pathway is of particular importance
for cartilage differentiation and growth in the metacarpals
and support the concept of molecular disease families
based on phenotypic similarities and interacting signaling
pathways.1
Our results thus add another condition to the PTHRP
pathway disease family. The observation that heterozygous
loss-of-function mutations in PTHLH result in a growth
defect that is very similar to that observed in GNAS muta-
tions suggests a particular importance for this component
of the pathway in the growth of bones of the hands and
feet. Other conditions with similar phenotypes, such as
acromicric dysplasia (MIM 102370) and acrodysostosis438 The American Journal of Human Genetics 86, 434–439, March 1(MIM 101800), may be caused by mutations in the same
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